DJIA 17,050.75 138.46 0.82%
NASDAQ 4,810.79 19.64 0.41%
S&P 500 2,013.43 17.60 0.88%
market minute promo

Merck & Co., Inc. (NYSE: MRK)

company name or ticker
Company Photos
(Click to zoom)

Thursday's ETF with Unusual Volume: XPH

Here's How Merck Plans to Protect Billions of Dollars in Sales

Merck has intriguing new diabetes drugs in development that could blunt any market share risk following Eli Lilly's positive phase 3 trial results for Jardiance.

Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter

Will the FDA Approve All 3 of These Cancer Drugs in October?

Three cancer drugs are slated to go before the proverbial firing squad in October. Will the Food and Drug Administration green light all three?

Pipeline Drugs Need To Fire For Johnson & Johnson’s Oncology Business

Why Merck Is A Dark Horse To Beat

ANI Pharmaceuticals Inks Deal with Merck for 2 NDAs

Inovio Gets Grant for Ebola Drugs, Regeneron Inks Deal

Eli Lilly Officially Puts Merck on Notice

Eli Lilly and partner Boehringer Ingelheim release their highly-anticipated EMPA-REG OUTCOME data on Jardiance, and it doesn't disappoint.

Merck Reports Encouraging Phase III Data on Bezlotoxumab

See More Articles...